866-997-4948(US-Canada Toll Free)

Metastatic Liver Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 53 Pages


Global Markets Directs, Metastatic Liver Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer. 

Metastatic Liver Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Liver Cancer.
  • A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Liver Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Liver Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Liver Cancer 7
Metastatic Liver Cancer Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Metastatic Liver Cancer Therapeutics Products under Development by Companies 13
Companies Involved in Metastatic Liver Cancer Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 14
Celsion Corporation 15
Aduro BioTech 16
Provectus Pharmaceuticals, Inc. 17
Transgene Biotek Ltd 18
Metastatic Liver Cancer Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
RG-7686 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
doxorubicin liposomal - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Provecta - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ANZ-100 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TBL-0404 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Metastatic Liver Cancer Therapeutics Drug Profile Updates 31
Metastatic Liver Cancer Therapeutics Discontinued Products 45
Metastatic Liver Cancer Therapeutics - Dormant Products 46
Metastatic Liver Cancer Product Development Milestones 47
Featured News & Press Releases 47
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 47
Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 47
Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 48
Feb 07, 2012: Aduro Announces Publication Of Phase I Trial Data Of ANZ-100 In Clinical Cancer Research 49
Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 49
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 50
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 51

Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Table


Number of Products Under Development for Metastatic Liver Cancer, H2 2013 7
Products under Development for Metastatic Liver Cancer Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
F. Hoffmann-La Roche Ltd., H2 2013 14
Celsion Corporation, H2 2013 15
Aduro BioTech, H2 2013 16
Provectus Pharmaceuticals, Inc., H2 2013 17
Transgene Biotek Ltd, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 23
Metastatic Liver Cancer Therapeutics Drug Profile Updates 31
Metastatic Liver Cancer Therapeutics Discontinued Products 45
Metastatic Liver Cancer Therapeutics Dormant Products 46

List of Chart


Number of Products under Development for Metastatic Liver Cancer, H2 2013 7
Products under Development for Metastatic Liver Cancer Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Assessment by Route of Administration, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Molecule Type, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *